Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$9.46

-0.34 (-3.47%)

08:20
11/06/18
11/06
08:20
11/06/18
08:20

Iovance Biotherapeutics to present new data on Phase 2 C-144-01 trial at SITC

Iovance Biotherapeutics announced that a presentation of new data from the ongoing Phase 2 lifileucel metastatic melanoma trial, or C-144-01, will occur at the Society for Immunotherapy of Cancer, or SITC. The most common treatment emergent adverse events observed in this cohort to date include chills, febrile neutropenia, anaemia, decreased platelet count, pyrexia, and hypophosphataemia. Two grade 5 events occurred. One was deemed not related to lifileucel by the investigator and the other possibly related.

  • 06

    Nov

IOVA Iovance Biotherapeutics
$9.46

-0.34 (-3.47%)

10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.
09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.
09/13/18
JEFF
09/13/18
NO CHANGE
Target $31
JEFF
Buy
Feedback on Moffitt TIL study appears positive, says Jefferies
Jefferies analyst Biren Amin hosted a call with an oncologist at Moffitt Cancer Center to review the initial data from this first non-small cell lung cancer tumor infiltrating lymphocytes study. The doctor highlighted the large unmet need in NSCLC patients who failed to respond to anti-PD-1 therapy and feels the 100% disease control rate achieved in the first eight refractory patients to nivo is promising, Amin tells investors in a research note. Further, the oncologist believes the limited duration of response could improve in a second NSCLC study incorporating key "biomarkers," the analyst points out. Amin believes Iovance Biotherapeutics could incorporate some of these key learnings into its two Phase I/II NSCLC studies. The analyst keeps a Buy rating on Iovance with a $31 price target.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.08

-0.76 (-0.28%)

12:45
11/16/18
11/16
12:45
11/16/18
12:45
General news
Markets bounce higher after Trump comments on China trade talks »

The markets moved higher…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.08

-0.76 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/16/18
11/16
12:45
11/16/18
12:45
General news
Breaking General news story  »

Week of 11/16…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says would like to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says does not want…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$20.54

-0.53 (-2.52%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
Options
4K Jun 22.5 calls on iQiyi trade $3.40 »

4K Jun 22.5 calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$138.09

-5.77 (-4.01%)

12:38
11/16/18
11/16
12:38
11/16/18
12:38
Hot Stocks
Definers says not hired by Facebook for opposition research »

Definers Public Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LYB

LyondellBasell

$94.38

0.95 (1.02%)

, BAK

Braskem

$27.66

0.56 (2.07%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell (LYB) is…

LYB

LyondellBasell

$94.38

0.95 (1.02%)

BAK

Braskem

$27.66

0.56 (2.07%)

PBR

Petrobras

$14.87

0.32 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$68.91

0.24 (0.35%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Options
Call buying in Cognizant Tech as the company hosts an Investor Day Friday »

Call buying in Cognizant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 26

    Nov

  • 02

    Dec

BAK

Braskem

$27.74

0.64 (2.36%)

, LYB

LyondellBasell

$94.44

1.01 (1.08%)

12:26
11/16/18
11/16
12:26
11/16/18
12:26
Hot Stocks
Breaking Hot Stocks news story on Braskem, LyondellBasell »

Braskem up 54c to $27.68…

BAK

Braskem

$27.74

0.64 (2.36%)

LYB

LyondellBasell

$94.44

1.01 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Periodicals
Airbus, Dassault plan to submit bid for early work on new jet, Reuters says »

Airbus and Dassault…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

LYB

LyondellBasell

$94.48

1.05 (1.12%)

12:24
11/16/18
11/16
12:24
11/16/18
12:24
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$54.66

-0.04 (-0.07%)

12:20
11/16/18
11/16
12:20
11/16/18
12:20
Options
Bearish option flow in Materials Sector ETF »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:20
11/16/18
11/16
12:20
11/16/18
12:20
General news
More from Evans: the short-term policy rate is the first instrument »

More from Evans: the…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/16/18
11/16
12:17
11/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/16/18
11/16
12:16
11/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$157.34

-2.06 (-1.29%)

12:09
11/16/18
11/16
12:09
11/16/18
12:09
Periodicals
Allergan wins ruling over generic Saphris, Bloomberg reports »

Allergan's Forest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$166.50

-36.15 (-17.84%)

, AMAT

Applied Materials

$34.39

-0.64 (-1.83%)

12:05
11/16/18
11/16
12:05
11/16/18
12:05
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened sharply…

NVDA

Nvidia

$166.50

-36.15 (-17.84%)

AMAT

Applied Materials

$34.39

-0.64 (-1.83%)

SONO

Sonos

$15.21

1.07 (7.57%)

PCG

PG&E

$23.93

6.16 (34.67%)

TRN

Trinity Industries

$22.61

0.87 (4.00%)

ACHC

Acadia

$30.63

-7.22 (-19.08%)

JWN

Nordstrom

$50.83

-8.14 (-13.80%)

WSM

Williams-Sonoma

$53.26

-7.34 (-12.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

JWN

Nordstrom

$51.02

-7.95 (-13.48%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Nordstrom falls -13.5% »

Nordstrom is down -13.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAIR

Wesco Aircraft

$9.54

-1.705 (-15.17%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Wesco Aircraft falls -15.2% »

Wesco Aircraft is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$24.00

6.23 (35.06%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Fitch downgrades PG&E Corp and utility sub to 'BBB-' on negative watch »

Fitch Ratings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$3.98

-0.735 (-15.59%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -15.3% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XME

SPDR S&P Metals & Mining

$31.10

0.15 (0.48%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Options
Bullish option flow in SPDR Metals and Mining Fund »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$130.80

20.3 (18.37%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 18.4% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVC

Natural Grocers

$20.28

3.62 (21.73%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Natural Grocers rises 21.7% »

Natural Grocers is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.